Taysha CEO steps down af­ter patent fights with pa­tient fam­i­lies, job cuts

Taysha Gene Ther­a­pies CEO RA Ses­sion II has re­signed fol­low­ing a tur­bu­lent year in which the com­pa­ny shelved most of its rare dis­ease pipeline and faced crit­i­cism from fam­i­lies for block­ing plans to restart a drug pro­gram.

Ses­sion, who will re­main a mem­ber of the board of di­rec­tors, will be suc­ceed­ed by Sean Nolan, the board’s chair­man. The changes are ef­fec­tive im­me­di­ate­ly, Taysha said Fri­day in a news re­lease. Nolan said his plans call for ex­pe­dit­ing the com­pa­ny’s lead pro­grams and strength­en­ing a re­cent part­ner­ship with Astel­las that brought in $50 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER